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OBJECTIVES: The eradication of Helicobacter (H.) pylori allows peptic ulcers in patients infected with the bacteria to
be cured. Treatment with the classic triple regimen (proton pump inhibitor, amoxicillin and clarithromycin) has shown
decreased efficacy due to increased bacterial resistance to clarithromycin. In our country, the eradication rate by
intention to treat with this regimen is 83%. In Brazil, a commercially available regimen for bacterial eradication that
uses levofloxacin and amoxicillin with lansoprazole is available; however, its efficacy is not known. Considering that
such a treatment may be an alternative to the classic regimen, we aimed to verify its efficacy in H. pylori eradication.
METHODS: Patients with peptic ulcer disease infected with H. pylori who had not received prior treatment were
treated with the following regimen: 30 mg lansoprazole bid, 1,000 mg amoxicillin bid and 500 mg levofloxacin,
once a day for 7 days.
RESULTS: A total of 66 patients were evaluated. The patients’ mean age was 52 years, and women comprised
55% of the sample. Duodenal ulcers were present in 50% of cases, and gastric ulcers were present in 30%. The
eradication rate was 74% per protocol and 73% by intention to treat. Adverse effects were reported by 49
patients (74%) and were mild to moderate, with a prevalence of diarrhea complaints.
CONCLUSIONS: Triple therapy comprising lansoprazole, amoxicillin and levofloxacin for 7 days for the eradication
of H. pylori in Brazilian peptic ulcer patients showed a lower efficacy than that of the classic triple regimen.
KEYWORDS: Peptic ulcer therapy; Helicobacter pylori drug effects; levofloxacin; amoxicillin therapeutic use and
adverse effects.
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’ INTRODUCTION
Curing peptic ulcers in patients infected with Helicobacter
(H.) pylori can be achieved by eradicating the bacteria (1).
This task is made easier using a triple regimen that includes
an antisecretory agent, which is most often a proton-pump
inhibitor (PPI), with two antibiotics (2). For years, the most
commonly used triple regimen has been called the ‘‘classic’’
regimen, which is the combination of a PPI, amoxicillin and
clarithromycin administered for 7 to 14 days (3).
In Brazil, the classic regimen has been used as the first-
choice therapy for approximately 10 years (4–6), preferably
with a treatment duration of 7 days provided as commercially
available blister packs containing the daily treatment of
4 capsules in the morning and 4 capsules in the evening (1 PPI
capsule, 2 capsules of amoxicillin and 1 capsule of clarithro-
mycin). This regimen is inexpensive, has few adverse effects
and has a per-protocol efficacy 485% (7–10). Treatment or
retreatment regimens that replace clarithromycin with nitroi-
midazole compounds are questionable, as evidence in our
country has shown a low eradication efficacy as a conse-
quence of the high prevalence of resistant bacteria (11–13). For
the retreatment of H. pylori infection when the classic
regimen fails, we have proposed regimens including PPIs
and furazolidone, tetracycline or levofloxacin, which have
shown good eradication rates in our country (14,15).
Overall, a worldwide increase in H. pylori resistance to
clarithromycin has been observed, causing a decrease in theDOI: 10.6061/clinics/2015(05)02
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efficacy of the classic regimen (16,17). In Brazil, this decrease
has not occurred homogeneously due to the size of the
country and the major health and socioeconomic differences
between regions. In our service, probably due to low
clarithromycin use in the treatment of other infections, the
classic regimen still shows a high eradication rate and low
primary resistance to clarithromycin (10,11).
A commercially available regimen that includes lansopra-
zole with amoxicillin and levofloxacin (18) with a 10-day
treatment duration was recently launched in the market as
a retreatment option when the classic regimen fails, but this
regimen has not been tested in Brazil as either a retreatment
or a first treatment. In the literature, this regimen has shown
good efficacy as both a first-choice treatment (19,20) and
a retreatment (21,22).
The objective of the present study was to assess the
eradication efficacy of treatment with 30 mg lansoprazole
bid, 1000 mg amoxicillin bid and 500 mg levofloxacin once
a day administered for 7 days in peptic ulcer patients
infected with H. pylori.
’ MATERIALS AND METHODS
Study population
Considering that the eradication efficacy expected for this
regimen is 85%, a sample approximately 70 patients was
proposed for the study to obtain a confidence level of 95%
and an error of 20%. All of the patients were recruited from
the outpatient clinic of the Division of Gastroenterology and
Clinical Hepatology, Hospital das Clínicas, Universidade de
São Paulo after being evaluated and agreeing to sign the free
and informed consent form approved by the hospital
Research Ethics Committee.
Inclusion criteria were as follows: being older than 14 and
younger than 85 years; being capable of understanding the
study objectives; having a peptic ulcer and being infected
with H. pylori.
Exclusion criteria were as follows: having undergone
previous eradication treatment for the bacteria; having
previously used quinolone compounds; having a compli-
cated ulcer; having undergone upper digestive tract surgery;
being pregnant or lactating; having symptomatic intestinal
or biliary diseases; having decompensated diseases, includ-
ing endocrine, respiratory, cardiac, and renal disease, among
others; continuously using anti-inflammatory drugs, even at
low doses; and having Los Angeles grade C or D esophagitis.
Study design
Because this study used an uncontrolled trial design, it
was not registered on international clinical trial sites.
After the initial visit, eligible patients underwent a 30-day
"wash-out" period after the use of PPIs or H2 blockers was
suspended; the patients were switched to antacids or
prokinetic drugs. After this period, the patients underwent
a videoendoscopy, during which gastric mucosa samples
were obtained to diagnose H. pylori infection by histopatho-
logical analysis and rapid urease testing. Patients with
positive results for both tests were considered infected.
On a second visit, after the inclusion and exclusion criteria
were assessed, the patients received the medications and
were properly advised regarding drug use, care and
treatment adherence. On a third visit, held one week later,
the patients were reassessed, the remaining pills were
counted, and adverse treatment effects were assessed. The
patients were also advised to avoid using other acid
suppressants, especially PPIs, as well as anti-inflammatory
drugs or other medications harmful to the digestive mucosa
until cured or controlled.
Twelve weeks after completing the antibiotic therapy,
patients underwent a C-13-labeled urea breath test, accord-
ing to a previously described technique (23). Patients with
negative test results then underwent endoscopy. Cases were
considered treatment failures if the breath test results were
positive, and such patients were referred for retreatment
with another eradication regimen. In cases for which there
was disagreement between the breath test assessment and
histological analysis control or rapid urease test results, the
patient underwent a new respiratory test after four weeks. If
the test was positive, it was considered a treatment failure;
and if negative, the patient was considered to be cured.
The presence of H. pylori in the initial and control
histological examination was evaluated by two pathologists
experienced in ulcer disease using hematoxylin-eosin (HE)
and Giemsa stains.
Treatment
Patients were treated with a commercial product, which is
sold in blister packs for daily use, containing a 30 mg capsule
of lansoprazole, one 500 mg capsule of levofloxacin and two
500 mg capsules of amoxicillin for use in the morning, and
one 30 mg capsule of lansoprazole and two 500 mg capsules
of amoxicillin for use at night. Enough medicine was
supplied for a seven-day treatment period.
Adverse effects assessment
Patient-reported adverse events were recorded and classi-
fied as mild when they did not hinder the patient’s daily
activities, moderate when they hindered the patient’s daily
activities but did not require the discontinuation of medica-
tion, and severe when they hindered the patient’s daily
activities and required treatment or the discontinuation of
medications.
Statistical analysis
Data were analyzed using the SPSS v.10 statistical
program, and the frequencies of categorical and continuous
variables were determined; the 95% confidence interval (CI)
was also calculated for the eradication rate.
Ethics
The study was approved by the Ethics Committee for
Analysis of Research Projects – CAPPesq – of Hospital das
Clínicas da Faculdade de Medicina da Universidade de São
Paulo. All patients were informed about the purpose of the
study and its methodology and agreed to sign the free and
informed consent form.
’ RESULTS
Seventy-one patients were invited to participate in the
study, but five were excluded: two because they had no
evidence of ulcer in the upper digestive endoscopy examina-
tion in the inclusion period and three because the H. pylori
detection tests were negative. Therefore, a total of 66 patients
were available for analysis, of which one did not return for
the control examinations.
The mean age of the patients was 52 years; there was a
predominance of women in the sample, and duodenal ulcers
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were identified in half of the cases (Table 1). The per-protocol
eradication rate was 74%, and the eradication rate by
intention to treat (ITT) was 73% (Table 2).
Forty-nine patients reported adverse events, all of which
were mild or moderate (Table 3). Complaints of diarrhea
(32%) and nausea (15%) were the most frequent.
’ DISCUSSION
The eradication rate (73%; CI: 62–84% per ITT) for the
triple regimen with lansoprazole, amoxicillin and levoflox-
acin found in our study was disappointing because eradica-
tion by ITT in our service was 82.7% with the classic regimen,
with a CI of 79–86%. Interestingly, a study carried out in our
country showed greater H. pylori resistance to levofloxacin
(23%) than to clarithromycin (8%) (11).
A weakness of this work was that it was not conducted as
a randomized, double-blind trial against the classical regi-
men; however, the effectiveness of that regimen has
remained relatively constant in our service.
The treatment duration was possibly a factor that determined
this lower efficacy, as the current tendency is to propose longer
treatment regimens for H. pylori eradication (24,25). However,
for both the classic treatment and other triple regimens, we
chose to focus on shorter-term treatments, aiming to obtain
lower costs, fewer adverse effects and greater adherence.
In our country, obtaining reliable information regarding
the previous use of levofloxacin may be difficult because this
antibiotic has been extensively used to treat respiratory
infections without the patient having specific knowledge of
its use. Thus, some patients in our sample may have
previously used this compound without knowing it. As we
could not determine strain susceptibility to levofloxacin in
this study, it was not possible to determine whether the low
treatment efficacy in this sample could be associated with
increased bacterial resistance to the antibiotic agent.
Evidence in the literature suggests that the secondary
resistance of H. pylori to levofloxacin may be low (26,27), but
studies also show high rates of primary resistance to
levofloxacin and low rates of efficacy in treating the bacteria
with this antibiotic (28,29).
There might have been a higher resistance of H. pylori to
amoxicillin in patients from our sample, as some Brazilian
studies have shown rates of resistance to this antibiotic of up
to 38% (12,30). However, we did not observe resistance to
amoxicillin in our service (11), and considering the good
efficacy of eradication using the classic regimen in our
country (10) with low bacterial resistance to clarithromycin
(11), the lower efficacy of the regimen with levofloxacin is not
likely due to high resistance to amoxicillin, even taking into
account the frequent use of this antibiotic in our country.
Considering the limitation that our study did not
determine the primary resistance of H. pylori to levofloxacin
and amoxicillin, the efficacy of the triple regimen with
levofloxacin was not superior to the classic regimen. Thus,
the classic treatment is still recommended as the first-line
treatment, and the triple regimen with levofloxacin is
indicated as a possible retreatment.
The adverse effects of treatment were frequent but were of
mild and moderate intensity, and none of the patients
participating in the study stopped taking the medication.
This finding is hardly surprising, as diarrhea and nausea are
expected adverse effects for levofloxacin (31), as well as for
amoxicillin (32), but they did not cause severe discomfort to
patients. However, Di Caro et al., when comparing the
adverse effects of similar treatments with quadruple therapy,
reported a much lower prevalence (33) of adverse effects.
The eradication of H. pylori using the lansoprazole,
amoxicillin and levofloxacin regimen for seven days in
previously untreated Brazilian peptic ulcer patients infected
with the bacteria showed low efficacy, with lower eradication
rates than those obtained with the classic triple regimen of a
PPI, amoxicillin and clarithromycin.
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Table 1 - Patient data.
Variable Value
Age
Mean 52 years
Range 19–82 years
Sex
Female 36 (55%)
Smoking 14 (21%)
Symptoms duration
Up 1 year 14 (21%)
1 to 5 years 16 (24%)
Over 5 years 36 (65%)
Ulcer type
Gastric 20 (30%)
Duodenal 33 (50%)
Gastric + duodenal 13 (20%)
Ulcer stage
Sakita A 8 (12%)
Sakita H 12 (18%)
Sakita S 46 (70%)
Table 2 - Eradication rates.
Rate 95% Confidence Interval
Per protocol 74% (48/65) 63–85%
Intention to Treat 73% (48/66) 62–84%
Table 3 - Adverse events.
Variable Value
Absent 17 (26%)
Mild 23 (35%)
Moderate 26 (39%)
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